Upcoming Events
Past Events
|
Mar 13, 2023
9:20 AM EDT
|
|
|
Feb 14, 2023
8:00 AM EST
|
|
|
Nov 8, 2022
8:00 AM EST
|
Listen to recording 16.5 MB
|
|
Sep 29, 2022
8:00 AM EDT
|
Listen to recording 11.7 MB
|
|
Nov 8, 2021
10:30 AM EST
|
Galecto will host a key opinion leader event to discuss the current treatment landscape for NSCLC, as well as the potential for GB1211, Galecto’s galectin-3 inhibitor that is expected to enter a phase 2 trial in 1H 2022. |
|
Jun 9, 2021
|
Galecto will host a key opinion leader event to discuss the current treatment landscape and unmet clinical need for myelofibrosis, as well as the potential for GB2064, Galecto’s LOXL2 inhibitor that is expected to enter a phase 2 trial in the current quarter. |
|
Mar 30, 2021
|